Sijó YA, Saurez MG, Velázquez ND, Méndez AL, Alfonso DA, Vargas BA, Robaina GM, Piedra SP, Lorenzo RA, Campos GA, Mendoza HI

Language: Spanish
References: 21
Page: 202-212
PDF size: 115.01 Kb.

ABSTRACT

Introduction: recombinant alpha erythropoietin is part of the treatment for anemia of prematurity. The use of this one in Cuba has been restricted and controversial as to schedule and dose.
Methods: prospective, non-randomized multicenter assay on the safety and efficacy of erythropoietin in the reduction of blood transfusion in very-low-weight preterm newborn. Seventy two neonates with gestational age under 34 post-menstruation weeks, weighing equal or less than 1 500 g, over 7 days of life after birth and fed on 50 mL/kg/day were included in the study.
Results: all of them received 300 U/kg erythropoietin by subcutaneous administration three times a week up to reaching 40 weeks of gestational age and an iron and vitamin supplement. Erythropoietin is very safe; it was just possibly related to slight retinopathy of prematurity, but overcome.
Conclusions: seven patients were transfused (9.7 %) in the course of study. The late use of erythropoietin in very-low-weight preterm child confirms its efficacy and safety.

REFERENCES

1. Plaisant F. Evolution of neonatal transfusion practices: current recommendations. Transfus Clin Biol. 2011;18:262-8.

2. Kotto-Kome AC, Garcia MG, Calhoun DA, Christensen RD. Effect of beginning recombinant erythropoietin treatment within the first week of life, among very-low-birth-weight neonates, on "early" and "ate" erythrocyte transfusions: a meta-analysis. J Perinatol. 2004;24:24-9.

3. Niederhauser C, Candotti D, Weingand T, Maier A, Tinguely C, Stolz M, et al. Reverse vertical transmission of hepatitis B virus (HBV) infection from a transfusion-infected newborn to her mother. J Hepatol. 2012;56:734-7.

4. Alarcon Allen A, Baquero-Artigao F. Review and guidelines on the prevention, diagnosis and treatment of post-natal cytomegalovirus infection. An Pediatr (Barc). 2011;74:52 e1-e13.

5. Fanaro S. Blood transfusion in infants: techniques and adverse events. J Matern Fetal Neonatal Med. 2011;24 Suppl 1:47-9.

6. Vazquez Lopez MA, Llamas MA, Galera R, Sanchez AR, Lendinez F, Gonzalez-Ripoll M, et al. Comparison between one and three doses a week of recombinant erythropoietin in very low birth weight infants. J Perinatol. 2011;31:118-24.

7. Tempera A, Stival E, Piastra M, De Luca D, Ottaviano C, Tramontozzi P, et al. Early erythropoietin influences both transfusion and ventilation need in very low birth weight infants. J Matern Fetal Neonatal Med. 2011;24:1060-4.

8. Fortes Filho JB, Eckert GU, Procianoy L, Barros CK, Procianoy RS. Incidence and risk factors for retinopathy of prematurity in very low and in extremely low birth weight infants in a unit-based approach in southern Brazil. Eye (Lond). 2009;23:25-30.

9. Schneider JK, Gardner DK, Cordero L. Use of recombinant human erythropoietin and risk of severe retinopathy in extremely low-birth-weight infants. Pharmacotherapy. 2008;28:1335-40.

10. Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2006:CD004863.

11. Brown MS, Baron AE, France EK, Hamman RF. Association between higher cumulative doses of recombinant erythropoietin and risk for retinopathy of prematurity. J AAPOS. 2006;10:143-9.

12. Von Kohorn I, Ehrenkranz RA. Anemia in the preterm infant: erythropoietin versus erythrocyte transfusion—it's not that simple. Clin Perinatol. 2009;36:111-23.

13. Bishara N, Ohls RK. Current controversies in the management of the anemia of prematurity. Semin Perinatol. 2009;33:29-34.

14. Mainie P. Is there a role for erythropoietin in neonatal medicine? Early Hum Dev. 2008;84:525-32.

15. Strauss RG. Controversies in the management of the anemia of prematurity using single-donor red blood cell transfusions and/or recombinant human erythropoietin. Transfus Med Rev. 2006;20:34-44.

16. Strauss RG. 2008 Emily Cooley Memorial Lecture: lessons learned from pediatric transfusion medicine clinical trials . . . a little child shall lead them. Transfusion. 2009;49:1996-2004.

17. Colectivo de Autores. Pediatría. VII ed. La Habana: Editorial Ciencias Médicas; 2006. p. 434-5.

18. Sola A ¿Qué sabemos en la actualidad de EPO para la anemia de la prematurez? En: Diálogos en Neonatología: aprendiendo de las preguntas. Buenos Aires: Edimed; 2009. p. 166.

19. Aher S, Ohlsson A. Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2006:CD004868.

20. Carbonell-Estrany X, Figueras-Aloy J, Alvarez E. Erythropoietin and prematurity—where do we stand? J Perinat Med. 2005;33:277-86.

21. Aher SM, Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2006:CD004865.